HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments.

Cancers (Basel) · 2024 · PMC11010911 · PMID 38611014

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

However, a numerical trend towards better results was observed in tumors with >30% cells stained than tumors with ≤30% staining [ 2 ].

also in 665 other papers

a positive trendno p-value reported

In the JACOB trial, adding pertuzumab to first-line chemotherapy plus trastuzumab in metastatic HER2-positive esophagogastric cancer failed to significantly improve overall survival in spite of a positive trend in PFS and ORR.

also in 5,550 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.